静脉β受体阻滞剂对心肌梗死预后的影响

The Effect of Injectingβ-acceptor Inhibitor on the Miocardial Infarction Prognosis.

目的早期应用静脉β受体阻滞剂,观察其对急性广泛前壁心肌梗死预后的影响。方法试验组选用符合急性广泛前壁心肌梗死病例53例,在入院后即给予静脉注射倍他乐克5mg,连用3次后,改为口服制剂。与未应用静脉β受体阻滞剂的病例相对照。结果试验组53例,显效30例,有效18例,无效5例,总有效率90.56%;对照组49例,显效16例,有效20例,无效13例,总有效率73.47%,χ2=5.17%,d=3.64,P<0.05,差别有显著性。经过疗效对比分析,治疗组总有效率明显优于对照组,两组间有显著性差异(P<0.05)。结论静脉β受体阻滞剂在急性广泛前壁心肌梗死的早期治疗中占有重要地位。只要没有禁忌证,无论是否实施溶栓或急诊PCI治疗者,都应尽早使用静脉加口服β受体阻滞剂,以期使患者获得额外的独立益处,进一步改善患者的预后。

Objective To investigate the effect of injectingβ - acceptor inhibitor on the acute extensive miocardial infarction prognosis. Methods 53 cases patients with acute extensive miocardial infarction were injected Betaloc 5mg, after 3 times, taken Betaloc orally. Betaloc was not applied in another 49 cases patients with acute extensive miocardial infarction. The curative effect was compared between the two groups. Results The efficient or inefficient ratio of the group with Betaloc or the group without Betaloc was 48/53, 5/53 or 36/ 49, 13/49 respectively. The difference was significant by x^2 test. Conclusions The patient with acute extensive miocardial infarction can get the extra good by means of early application of β - acceptor inhibitor except the patient with no - no of the application of Betaloc.